Statement by the Board of Directors of Meda in relation to the public offer by Mylan
The Board of Directors of Meda unanimously recommends that the shareholders of Meda accept the offer made by MylanBackground This statement is made by the Board of Directors (the “Board”) of Meda AB (publ.) (“Meda” or the “Company”) pursuant to Section II.19 of Nasdaq Stockholm’s Takeover Rules (the “Takeover Rules”). Mylan N.V., a leading global pharmaceutical company whose ordinary shares (“Mylan Shares”) are traded on the NASDAQ Global Select Market and the Tel Aviv Stock Exchange under the symbol “MYL”, has today announced a public offer to the shareholders of Meda to transfer all